Drugs / GLIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03091933 | Feb 2017 → Mar 2018 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, adult acute lymphoblastic leukemia +2 | Ciusss de L'Est de l'Île de Montréal | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLIDE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03091933 ↗ |
| Modality | Cell therapy | “anti- Minor histocompatibility (MiHA) cell line” NCT03091933 ↗ |
| Route | Intravenous | “administered as a single infusion” NCT03091933 ↗ |